Trial Rationale

Current guidelines state that non-vitamin K antagonist oral anticoagulant (NOAC) therapy is the first line option for treatment of stroke risk reduction in non‑valvular atrial fibrillation (NVAF) patients. However, bleeding risk on these therapies compounds year over year, and are comparable across current pharmacotherapy options.
The bleeding risk associated with anticoagulants compounds year over year graph
*The HAS-BLED scoring system predicts a patients risk of stroke while on warfarin.
**Assumes constant risk despite increasing age, and bleeding risk is independent from bleeding risk in previous years.

  
bleeding chart
  

The CHAMPION‑AF clinical trial seeks to demonstrate WATCHMAN FLXTM is a first‑line stroke risk reduction therapy for most NVAF patients.

With this trial, Boston Scientific expands its LAAC leadership with unmatched clinical evidence intended to demonstrate WATCHMAN FLX is the optimal choice versus NOAC for lifelong stroke risk reduction.

  

Why LAA Closure?

With ~40% of oral anticoagulant (OAC) indicated patients left unprotected from stroke due to dissatisfaction and non-adherence with OACs, CHAMPION‑AF seeks to show WATCHMAN FLX as a first‑line option for stroke risk-reduction in most NVAF patients.7

Over 100,000 patients have already been successfully treated with WATCHMANTM LAAC technology.

  

Why CHAMPION-AF?

WATCHMAN device and NOACs
CHAMPION-AF is the largest left atrial appendage closure (LAAC) device trial that evaluates WATCHMAN FLX vs. NOAC as a first-line stroke risk reduction option for most NVAF patients.
  
Find a Trial Site

Find a Trial Site

Boston Scientific has selected US sites to be CHAMPION-AF investigational centers. If you have a candidate in mind, view the active trial list provided by clinicaltrials.gov, and reach out to a study physician near you to discuss next steps for referral.

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the u.S. Adult population. The American journal of cardiology. 2013;112:1142-1147
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation—executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854-906
3. Patel, M. NEJM 2011; 365(10): 883-891.
4. Granger, C. NEJM 2011; 365(11): 981-992.
5. Connolly, S. NEJM 2009; 361(12): 1139-1151.
6. Giugliano, R. NEJM 2013; 369(22): 2093-2104.
7. Marzec, et al. JACC 2017: 69(20): 2475-2484.


  

WATCHMAN FLX is an FDA approved device being studied for an expanded indication as a first line therapy vs NOAC for NVAF patients. The use of WATCHMAN or WATCHMAN FLX as a first-line therapy for stroke risk reduction in NVAF patients is considered investigational. 

Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.


INTENDED USE/INDICATIONS FOR USE

The WATCHMAN FLX Device is indicated to reduce the risk of thromboembolism from the left atrial ae in patients with non-valvular atrial fibrillation who:

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are nded for anticoagulation therapy;
  • Are deemed by their physicians to be suitable for anticoagulation therapy; and
  • Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy, into account the safety and effectiveness of the device compared to anticoagulation therapy.


CONTRAINDICATIONS

Do not use the WATCHMAN FLX Device if:

  • Intracardiac thrombus is present.
  • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device int.
  • The LAA anatomy will not accommodate a Closure Device (see Table 45 of the eIFU).
  • The patient has a known hypersensitivity to any portion of the device material or the individual comp(see Device Description section of the eIFU) such that the use of the WATCHMAN FLX Device is contraindicated.
  • Any of the customary contraindications for other percutaneous catheterization procedure (e.g., patie too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
  • There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12 inhibitor.


WARNINGS

Implantation of the WATCHMAN FLX Device should only be performed by interventional cardiologi/ or electrophysiologists who are trained in percutaneous and transseptal procedures and who have completed the WATCHMAN FLX Physician Training program.

  • This device has not been studied in pregnant or breastfeeding women. Careful consideration should be g use of the Closure Device in pregnant and/ or breastfeeding women due to the risk of significant exposure to x-rays and the use of anticoagulation medication.
  • Device selection should be based on accurate LAA measurements obtained using echocardiographic imaging e in multiple views (TEE recommended in multiple angles [e.g., 0°, 45°, 90°, 135°]) to avoid improper Closure Device sizing.
  • Do not release (i.e., unscrew) the WATCHMAN FLX Device from the core wire unless all release c are satisfied to avoid suboptimal results.
  • Potential for Closure Device embolization exists with cardioversion < 30 days following Clovice implantation; verify Closure Device position after cardioversion during this period.
  • Appropriate post-procedure drug therapy should be followed. See Post-Procedure Information section (oIFU) for further detail.


PRECAUTIONS

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been estd in patients for whom long-term anticoagulation is determined to be contraindicated.
  • The LAA is a thin-walled structure. Use caution when accessing the LAA, and deploying, recap and repositioning the Closure Device.
  • Use caution when introducing a WATCHMAN Access System to prevent damage to cardiac structures.
  • Use caution when introducing the Delivery System to prevent damage to cardiac structures.
  • To prevent damage to the Delivery Catheter or Closure Device, do not allow the WATCHMAN FLX Device rude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
  • If using a power injector, the maximum pressure should not exceed 100 psi.


PATIENT SELECTION FOR TREATMENT

In considering the use of the WATCHMAN FLX Device, the rationale for seeking an alternative tterm anticoagulation therapy and the safety and effectiveness of the device compared to anticoagulation should be taken into account.

  • The presence of indication(s) for long-term anticoagulation therapy, other than non-valvular atrial fiion (e.g. mechanical heart valve, hypercoagulable states, recurrent deep venous thrombosis).

Details regarding the indications, contraindications, warnings, and precautions for oral anticoagulanoved for patients with non-valvular atrial fibrillation are provided in their respective Instructions for Use. Of note:

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been estd in patients for whom long-term anticoagulation is determined to be contraindicated.
  • Factors that need to be considered for the WATCHMAN FLX Device and implantation procedure include the ng:

  • Overall medical status, including conditions which might preclude the safety of a percutaneous, treter procedure.
  • Suitability for percutaneous, transseptal procedures, including considerations of:
    • Cardiac anatomy relating to the LAA size and shape.
    • Vascular access anatomy (e.g., femoral vein size, thrombus, or tortuosity).
    • Ability of the patient to tolerate general or local anesthesia.
    • Ability of the patient to undergo required imaging.
  • Ability to comply with the recommended post-WATCHMAN FLX Device implant pharmacologic regimen (see Posdure Information section) especially for patients at high risk for bleeding.


ADVERSE EVENTS

Potential adverse events (in alphabetical order) which may be associated with the use of a left atriadage closure device or implantation procedure include but are not limited to:

  • Air embolism
  • Airway trauma
  • Allergic reaction to the contrast media, anesthetic, WATCHMAN Implant material, or medications
  • Altered mental status
  • Anemia requiring transfusion
  • Anesthesia risks
  • Angina
  • Anoxic encephalopathy
  • Arrhythmias
  • Atrial septal defect
  • Bruising, hematoma, or seroma near the catheter insertion site
  • Cardiac perforation
  • Chest pain/discomfort
  • Confusion post procedure
  • Congestive heart failure
  • Contrast related nephropathy
  • Cranial bleed
  • Death
  • Decreased hemoglobin
  • Deep vein thrombosis
  • Device embolism
  • Device fracture
  • Device thrombosis
  • Edema
  • Embolism
  • Excessive bleeding
  • Fever
  • Fistula
  • Groin pain
  • Groin puncture bleed
  • Hematuria
  • Hemoptysis
  • Hypotension
  • Hypoxia
  • Improper wound healing
  • Inability to reposition, recapture, or retrieve the device
  • Infection/pneumonia
  • Interatrial septum thrombus
  • Intratracheal bleeding
  • Major bleeding requiring transfusion
  • Misplacement of the device/improper seal of the appendage/movement of device from appendage wall
  • Myocardial erosion
  • Nausea
  • Oral bleeding
  • Pericardial effusion/tamponade
  • Pleural effusion
  • Prolonged bleeding from a laceration
  • Pseudoaneurysm
  • Pulmonary edema
  • Renal failure
  • Respiratory insufficiency/failure
  • Stroke - Hemorrhagic
  • Stroke - Ischemic
  • Surgical removal of the device
  • TEE complications (e.g., throat pain, bleeding, esophageal trauma)
  • Thrombocytopenia
  • Thrombosis
  • Transient ischemic attack (TIA)
  • Valvular or vascular damage
  • Vasovagal reactions

There may be other potential adverse events that are unforeseen at this time.

92574167 C.2

Top